Epidemiology of virologically confirmed RSV, influenza and COVID-19 in adults in England, 2023–2024: Primary Care Observational Study of Acute Respiratory Infection (ObservatARI)
During the 2023/24 winter season in England, medically-attended RSV presented a significant disease burden, with a positivity comparable to SARS-CoV-2 and approximately 70% of influenza. Given well-established vaccination programmes for influenza and COVID-19, these findings demonstrate an opportunity to introduce an RSV vaccination programme for adults.
Authors
- Xuejuan Fan
- Uy Hoang (ORCID: https://orcid.org/0000-0002-8428-5140)
- Jade Cogdale
- Gavin Jamie (ORCID: https://orcid.org/0000-0001-9147-7784)
- William H. Elson (ORCID: https://orcid.org/0000-0002-8630-1378)
- Elizabeth Button (ORCID: https://orcid.org/0000-0003-0777-2508)
- Beatrix Kele (ORCID: https://orcid.org/0000-0003-1273-7299)
- Andre B. Araujo (ORCID: https://orcid.org/0000-0002-5967-4806)
- Gu Xinchun
- Rachel Byford (ORCID: https://orcid.org/0000-0002-4792-8995)
- Fatima Batool (ORCID: https://orcid.org/0000-0002-3108-9701)
- Ahreej Eltayeb (ORCID: https://orcid.org/0009-0009-3624-9186)
- Simon de Lusignan
- Praveen SEBASTIAN-PILLAI
- Orsolya BALOGH
- Tiina TALTS
- Jennifer M. RADIN
- Filipa FERREIRA
- Ellya ENESCA
- José M. ORDÓÑEZ-MENA
- David MARTIN
- Joan MADIA
- Maria ZAMBON
- LU Tianyi
Institutions
- Public Health England (GB)
- University of Oxford (GB)
- Moderna Therapeutics (United States) (US)
- Modern Water (United Kingdom) (GB)
- Royal College of General Practitioners (GB)
Publication Details
- Journal
- Journal of Infection
- Published
- 2026-02-21
- DOI
- https://doi.org/10.1016/j.jinf.2026.106714
- Primary Topic
- Respiratory viral infections research
- Type
- article
- Field-Weighted Citation Impact
- 0.00